Hualan Biological Engineering Inc.

Shenzhen Stock Exchange 002007.SZ

Hualan Biological Engineering Inc. Interest Coverage Ratio for the year ending December 31, 2023: 157.30

Hualan Biological Engineering Inc. Interest Coverage Ratio is 157.30 for the year ending December 31, 2023, a 220.50% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Hualan Biological Engineering Inc. Interest Coverage Ratio for the year ending December 31, 2022 was 49.08, a -37.28% change year over year.
  • Hualan Biological Engineering Inc. Interest Coverage Ratio for the year ending December 31, 2021 was 78.26, a -81.89% change year over year.
  • Hualan Biological Engineering Inc. Interest Coverage Ratio for the year ending December 31, 2020 was 432.15, a 90.72% change year over year.
  • Hualan Biological Engineering Inc. Interest Coverage Ratio for the year ending December 31, 2019 was 226.58, a -6.83% change year over year.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Loading...
Shenzhen Stock Exchange: 002007.SZ

Hualan Biological Engineering Inc.

CEO Ms. Bei Fan
IPO Date June 25, 2004
Location China
Headquarters No. 1 Hualan Avenue A
Employees 3,709
Sector Health Care
Industries
Description

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company's vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine. The company has strategic alliance with the Chinese Academy of Sciences, and other scientific research institutes and scientific research companies. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.

Similar companies

000538.SZ

Yunnan Baiyao Group Co.,Ltd

USD 7.83

2.23%

300122.SZ

Chongqing Zhifei Biological Products Co., Ltd.

USD 3.45

3.36%

000963.SZ

Huadong Medicine Co., Ltd

USD 4.53

2.64%

002001.SZ

Zhejiang NHU Company Ltd.

USD 2.97

0.01%

000661.SZ

Changchun High-Tech Industries (Group) Inc.

USD 12.91

2.15%

StockViz Staff

January 16, 2025

Any question? Send us an email